Quest Diagnostics Incorporated (DGX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Diagnosticssrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 3.27% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Quest Diagnostics’ Quarterly Earnings Preview: What You Need to Know
- Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials
- Who We Play For and Myelai Launch Heart Screening Program at Quest Diagnostics in Tampa as Florida Becomes First State to Require ECGs for High School Athletes
- Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally?
- Quest Diagnostics (DGX) Could Be 5% Below Fair Value After Apple Health Launch
- Why Quest Diagnostics Holdings Stock Dropped Today
- NICU Genetic Testing Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)
- Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Quest Diagnostics Incorporated.
Full DGX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.